Skip to navigation Skip to content

Indications, Dosing, Etc.

Diagnosis & Management Healthcare Professional App

Download this unique, FREE tool and resource that provides important information about the diagnosis and management of multiple sclerosis for practicing clinicians. The app is a concise compilation of current, easy-to-reference, evidence-based information that you can access at no charge for iOS or Android.

App production made possible by Allergan, Bayer HealthCare, Novartis and Questcor Pharmaceuticals, Inc.

Download for iPhone

Download for Android


In this article


This page lists FDA-approved DMTs: Indications, Dosing, Route of Administration, and Pregnancy Rating.

*Relapsing forms include relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS), and progressive-relapsing MS (PRMS), in those patients who continue to have relapses.

Alemtuzumab (Lemtrada)

  • Prescribing Information
  • Indications:
    • Relapsing forms of MS*
    • Generally reserved for patients who have had an inadequate response to two or more disease-modifying therapies
    • Study 1
    • Study 2
  • Dosing: 12 mg/day 5 consecutive days followed by 12 mg/day for 3 consecutive days one year later
  • Route of Administration: IV
  • Pregnancy Category: C


Daclizumab (Zinbryta)

Zinbryta (daclizumab) was withdrawn from the worldwide market on March 2, 2018. Please see important information about the withdrawal in our Society News.

Prescribing Information
Indications: Adult patients with relapsing forms of MS*
      Study 1
      Study 2
Dosing: 150 mgs once a month
Route of Administration: subcutaneous injection
Pregnancy Category: None – due to the change in FDA reporting of pregnancy/lactation data


Dimethyl fumarate (Tecfidera)

Fingolimod (Gilenya)

Glatiramer acetate (Copaxone; Glatopa -- generic equivalent for 20mg dose)

Interferon b-1a (Avonex)

Interferon b-1a (Rebif)

Interferon b-1b (Betaseron)

Interferon b-1b (Extavia)

Mitoxantrone (Novantrone)

Natalizumab (Tysabri)

Ocrelizumab (Ocrevus)

  • Prescribing Information
  • Indications:
  • Dosing: 600mg every 6 months
  • Route of Administration: IV
  • Pregnancy Category: No category assigned due to changes to FDA labeling procedures for pregnancy and lactation. No human data: in monkeys, administration of doses 2-10 times the human dose by weight during organogenesis and continuing through the neonatal period resulted in perinatal deaths, renal toxicity, lymphoid follicle formation in the bone marrow and severe decreases in circulating B-lymphocytes in neonates.

Pegylated Interferon b-1a (Plegridy)

  • Prescribing information
  • Indications:
    • Relapsing forms of MS
    • Dosing: 125 mcg q 14 days with initial titration (63 mcg Day 1; 94 mcg Day 15; 125 mcg Day 29 and q 14 days thereafter
  • Route of Administration: SQ
  • Pregnancy Category C

Teriflunomide (Aubagio)